Transgenic Group Inc. (TYO:2342)
300.00
-3.00 (-0.99%)
At close: Feb 6, 2026
Transgenic Group Revenue
Transgenic Group had revenue of 3.03B JPY in the quarter ending September 30, 2025, a decrease of -11.72%. This brings the company's revenue in the last twelve months to 12.92B, down -0.76% year-over-year. In the fiscal year ending March 31, 2025, Transgenic Group had annual revenue of 13.01B, down -0.60%.
Revenue (ttm)
12.92B
Revenue Growth
-0.76%
P/S Ratio
0.39
Revenue / Employee
53.60M
Employees
241
Market Cap
5.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 13.01B | -78.00M | -0.60% |
| Mar 31, 2024 | 13.08B | 1.65B | 14.47% |
| Mar 31, 2023 | 11.43B | -1.15B | -9.12% |
| Mar 31, 2022 | 12.58B | 1.53B | 13.85% |
| Mar 31, 2021 | 11.05B | - | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Linical | 9.87B |
| Kohjin Bio | 5.20B |
| Soiken Holdings | 4.87B |
| OncoTherapy Science | 956.00M |
| PRISM BioLab Co.,LTD | 677.33M |
| Carna Biosciences | 544.45M |
| D. Western Therapeutics Institute | 419.76M |
| Noile-Immune Biotech | 7.00M |